Head and neck neoplasm

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-phase trial tests whether a new drug (ATRN-119) combined with a single, precise dose of radiation to the neck can safely and effectively treat early-stage HPV-positive throat cancer before surgery. About 35 participants will take the drug daily for 10 days and receive …

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This large Phase 3 trial is testing a new drug called APG-157, given as a pastille that dissolves in the mouth, for people with advanced head and neck cancer. The study will see if adding APG-157 before and after standard treatments (surgery or chemoradiation) helps keep the canc…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This trial tests whether giving trilaciclib before chemotherapy and immunotherapy can protect bone marrow in people with advanced head and neck cancer. The goal is to reduce dangerous drops in blood cell counts, allowing patients to receive their full chemo doses on schedule. Abo…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This phase 2 trial tests whether adding MRG003 (a targeted drug) to toripalimab (an immunotherapy) before surgery can shrink tumors more than toripalimab alone in people with PD-L1-positive, locally advanced head and neck cancer. Participants receive two cycles of either the comb…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This phase II trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to people with advanced hypopharyngeal cancer. The goal is to shrink tumors enough to improve surgical outcomes and possibly preserve the voice box. About 52 participants will receive thre…

This phase 2 trial tests a new approach for people with advanced sinonasal cancer (a rare cancer of the nasal cavity and sinuses). Before surgery, patients receive standard chemotherapy (docetaxel and cisplatin) plus two immunotherapy drugs (sintilimab and ipilimumab). The goal i…

This early-phase trial tests whether adding axelopran—a drug that blocks opioid effects on the immune system—can help pembrolizumab (an immunotherapy) work better in people with advanced head and neck cancer who take opioids for pain. About 18 participants will receive both drugs…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This study tests a new drug called SKB571 in 30 adults with head and neck cancer that has returned or spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for response and…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This phase 3 trial tests whether a personalized radiation plan, which expands the treatment area based on each patient's tumor margins, can control nasopharyngeal cancer as well as the standard approach. The study includes 568 adults with newly diagnosed, non-metastatic disease. …

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This trial tests whether a special dye called indocyanine green (ICG), injected during surgery, helps surgeons see blood flow in reconstructed tissue better than standard checks. About 244 adults having head and neck reconstruction will be randomly assigned to get the dye or stan…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests whether a blood test that detects HPV DNA can help doctors choose the right treatment for people with HPV-positive oropharyngeal cancer. About 116 participants with stage I to III cancer will receive either the immunotherapy drug pembrolizumab (Keytruda) or stand…

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This phase 2 trial tests whether the drug becotatug vedotin can prevent cancer from returning in 140 patients with high-risk nasopharyngeal carcinoma who have completed standard chemo-radiation. Participants are randomly assigned to receive the drug or standard care. The main goa…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This study tests a new treatment plan for people with HPV-positive oropharyngeal cancer (a type of throat cancer linked to HPV). The plan combines an immune-boosting drug (nogapendekin alfa inbakicept), a vaccine targeting HPV, chemotherapy, and a lower dose of radiation. The goa…

This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate p…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study looks at the best way to treat people with p53-mutant oral dysplasia (abnormal cells in the mouth) and early-stage oral cancer. About 636 adults will be placed into three groups based on their diagnosis and receive either monitoring, surgery, or surgery plus neck disse…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This study tests whether giving a combination of anlotinib (a targeted therapy) and epirubicin (chemotherapy) before surgery can improve outcomes for people with advanced sinonasal adenoid cystic carcinoma, a rare and aggressive cancer of the nasal cavity and sinuses. About 76 pa…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several w…

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This study tests a special hydrogel that acts like a glue to hold eye tissues together during surgery, avoiding the need for stitches. Stitches can cause pain, swelling, and scarring, but this gel uses light to bond quickly and gently. The trial will include 20 people with cornea…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This study tests a new drug called TQB2922, given as a shot under the skin, for people with head and neck cancer that has come back or spread. The drug is a special antibody that targets two proteins (EGFR and c-Met) involved in cancer growth. The trial has two parts: first, find…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This study tests whether giving two drugs (becotatug vedotin and pucotenlimab) before surgery can shrink tumors in people with recurrent head and neck cancer that has stopped responding to standard treatments. About 42 adults with EGFR-positive cancer will receive 3 cycles of the…

This Phase III trial will compare proton beam radiotherapy with standard photon radiotherapy in 504 patients with non-metastatic nasopharyngeal carcinoma. The goal is to see if proton therapy reduces toxic side effects and improves survival. Participants will be randomly assigned…

This study tests a combination of two drugs, nemtabrutinib and rituximab, in about 35 adults with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs by mouth and thro…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase II trial tests whether combining two drugs—pucotenlimab (an immunotherapy) and becotatug vedotin (a targeted chemotherapy)—given before and after surgery can improve outcomes for people with locally advanced head and neck cancer. About 80 participants will receive eith…

This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the ri…

This phase II trial tests a combination of an antibody-drug conjugate (a targeted cancer drug) and stereotactic body radiotherapy (precise, high-dose radiation) in 40 people with recurrent or metastatic salivary gland cancer. Participants first receive the drug; if their disease …

This study looks at whether patients with a rare nasal cancer (sinonasal adenoid cystic carcinoma) can safely avoid radiation after surgery if the tumor was completely removed. About 200 patients will choose either surgery alone or surgery plus radiation, and researchers will tra…

This phase 2 trial tests a combination of two drugs, XL-092 and pembrolizumab (Keytruda), given before surgery to people with a type of oral cancer that is HPV-negative and can be removed. The goal is to see if the drugs can shrink or eliminate the tumor before the operation. Abo…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This phase 2 trial is testing a drug called ivonescimab in 42 people with a type of head and neck cancer (nasopharyngeal carcinoma) that has stopped responding to standard immunotherapy and chemotherapy. The drug is given every 3 weeks by IV. Researchers will measure how many pat…

This study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation t…

This study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This study tests whether adding the drug benmelstobart to standard radiotherapy and nimotuzumab can help prevent head and neck cancer from coming back after surgery. About 386 patients with intermediate-risk features will be randomly assigned to one of two groups. The main goal i…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This phase 2 trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to a special type of radiation and standard chemotherapy can help people with advanced, bulky head and neck cancer live longer without the disease getting worse. The study will enroll 2…

This study tests whether giving radiation along with immunotherapy before surgery works better than immunotherapy alone for people with advanced head and neck cancer. About 36 adults with treatable but advanced cancer will be split into two groups. The goal is to see if the combi…

This study tests a new treatment for people whose nasopharyngeal cancer has come back and cannot be surgically removed. Participants will receive two cycles of a targeted drug (becotatug vedotin) plus an immunotherapy, followed by radiation and continued immunotherapy. The goal i…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) and a targeted therapy (anlotinib) to standard chemotherapy and radiation can help prevent cancer from returning in people with high-risk, advanced nasopharyngeal carcinoma. About 442 adults aged 18-65 …

This study tests whether giving two drugs together before surgery can shrink advanced mouth or throat cancers. The drugs are becotatug vedotin and pucotenlimab. About 26 people with stage III or IVa cancer will take part. The goal is to see if the cancer nearly or completely disa…

This study tests whether giving two drugs (vibecortamab and putilimab) before surgery can help shrink tumors in people with locally advanced laryngeal cancer. About 10 adults aged 18-80 with resectable cancer will receive the combination, then have surgery. The main goal is to se…

This phase 2 trial tests whether a combination of two chemotherapy drugs, cyclophosphamide and etoposide, can control advanced head and neck cancer in adults who have already tried standard treatment. 120 participants will receive either the drug combo or methotrexate for 6 month…

This study tests a new treatment for people whose nose and throat cancer has returned and cannot be removed with surgery. The treatment combines an immunotherapy drug (PD-1 antibody) with two chemotherapy drugs, followed by targeted radiation. The goal is to see if this approach …

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests whether adding ficerafusp alfa to the immunotherapy nivolumab can shrink tumors better than nivolumab alone in people with advanced head and neck cancer that has stopped responding to platinum chemotherapy. About 131 adults aged 18-75 will take part. The goal is …

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This Phase 3 trial tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can improve outcomes for people with high-risk nasopharyngeal cancer. About 514 participants will be randomly assigned to receive either the new combo or stan…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This study will test whether a special endoscopic (scope-based) surgery can completely remove tumors in difficult areas of the nose and sinuses. About 25 adults with these tumors will take part. Researchers will measure how often the tumor is fully removed, how much blood is lost…

This study tests whether giving the immunotherapy drug nivolumab before surgery can shrink tumors in people with advanced oral cancer. About 60 adults with resectable oral squamous cell carcinoma will receive nivolumab, then have surgery. Researchers will also look for biomarkers…

This study tests whether adding a targeted drug (cetuximab) to standard immunotherapy (pembrolizumab or finotonlimab) and chemotherapy helps people with advanced head and neck cancer live longer without their cancer growing. About 316 adults aged 18-70 with cancer that has spread…

This phase II trial is testing a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this 3-week course is safe and effective at controlling the cancer while pos…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This trial tests whether adding natural killer (NK) cells from healthy donors to standard chemoradiotherapy can reduce the risk of cancer returning in people with advanced nasopharyngeal cancer. The study has two phases: first, finding the safest dose of NK cells, then testing th…

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This study tests whether a special scan (SPECT-CT) can show which side of the neck needs radiation in people with oropharyngeal cancer. Currently, both sides are treated to prevent hidden cancer spread, but this causes more side effects. The trial will enroll 128 patients to see …

This Phase 2 trial tests an experimental iron nanoparticle injection (CNSI-Fe) given directly into tumors along with standard radiotherapy. The goal is to see if the combination shrinks tumors better than radiation alone. The study will enroll 52 adults with head and neck cancer …

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This study tests whether a mixed reality system, similar to video game technology, can help surgeons remove oral cancer and rebuild the area more accurately. Thirty people with oral cancer will be split into three groups: one using mixed reality, one using a virtual surgical guid…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This study tests a combination of three drugs (chidamide, toripalimab, and anlotinib) in 52 adults with recurrent or metastatic nasopharyngeal carcinoma that has failed at least one prior treatment. The goal is to find the safest dose and see how many patients' tumors shrink. Par…

This study tests a low-cost approach to treat pre-cancerous and cancerous mouth lesions using a drug (5-ALA) that makes abnormal cells sensitive to light, followed by laser light delivered through a handheld device. The goal is to destroy these lesions without surgery. The trial …

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This study looks at people with advanced mouth or throat cancer who had chemotherapy and immunotherapy before surgery. After surgery, they will either get radiation, immunotherapy maintenance, or just be watched. The goal is to see which approach helps them live longer without th…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests whether adding fianlimab to the immunotherapy cemiplimab works better than cemiplimab alone at preventing cancer return in people with HPV-positive head and neck cancer who have signs of leftover cancer after initial treatment. About 68 adults will receive either…

This study tests whether adding the immunotherapy drug camrelizumab to either an EGFR antibody or chemotherapy helps people with advanced head and neck cancer live longer. About 246 adults with stage III or IV head and neck cancer will receive the treatment before and after surge…

This study tests a new approach for people with a certain type of throat cancer that is not low-risk. Participants first receive a combination of chemotherapy, immunotherapy, and a special type of radiation called lattice radiotherapy. Then, based on how much the tumor shrinks, t…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This Phase 3 trial tests whether giving a short course of targeted radiation (SBRT) followed by chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced oral or HPV-negative throat cancer. About 184 participants will be randomly assigned to rece…

This Phase 2 trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and Pucotenlimab (an immunotherapy)—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study will enroll 30 adults and measure how long the cancer stay…

This phase 2 trial tests whether giving a combination of the immunotherapy drug camrelizumab and two chemotherapy drugs (paclitaxel and carboplatin) before surgery can improve outcomes for people with advanced oral cavity or larynx cancer. Fifty participants will receive three cy…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This study tests a combination of a modified virus (H101) and a targeted chemotherapy procedure (TACE) in 20 adults with head and neck cancer that has returned or spread after at least two standard treatments. The goal is to shrink tumors and boost the immune system while limitin…

This Phase II trial tests whether giving the immunotherapy drug toripalimab on different days during chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 198 participants will receive standard chemotherapy plus toripalimab on Day 1, Day 5, or Da…

This study tests whether a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery can shrink or eliminate tumors in people with advanced head and neck cancer. About 30 adults aged 18-70 with stage III/IVA disease who have not had prior tr…

This phase 2 trial tests whether combining two drugs—scipibaimab and tislelizumab—can shrink tumors in people with recurrent or metastatic nasopharyngeal carcinoma that has worsened after first-line treatment. About 37 adults whose cancer has not responded to platinum chemotherap…

This phase 2 trial tests a drug called becotatug vedotin, given alone or with immune-boosting drugs (penpulimab or ivonescimab), before surgery for head and neck cancer. The goal is to see if these treatments can shrink tumors or even make them disappear completely. The study inv…

This Phase 3 trial will test whether adding anlotinib (a drug that cuts off tumor blood supply) to standard immunotherapy and chemotherapy with radiation can improve outcomes for 412 people with high-risk nasopharyngeal cancer. Participants will receive either the new combo or st…

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and docetaxel) is safe and tolerable as an initial treatment for people with advanced head and neck cancer. The study enrolls 26 adults whose tumors have a certain prote…

This phase II trial tests the immunotherapy drug sintilimab combined with radiotherapy in patients with resectable locally advanced head and neck cancer. Participants receive sintilimab before surgery, then again after surgery along with radiation. The study aims to see if this a…

This phase 3 trial will test whether a shorter course of the immunotherapy drug tislelizumab, combined with chemotherapy and radiation, works as well as a longer course for people with advanced nasopharyngeal cancer. About 418 participants will be randomly assigned to receive eit…

This early-phase study tests a new type of radiation (lattice radiotherapy) given with chemotherapy and immunotherapy before surgery for oral cavity cancer. About 30 adults with advanced but removable tumors will receive different radiation doses to find the safest level. The goa…

This study tests whether adding chemotherapy to the immunotherapy drug toripalimab before surgery helps keep head and neck cancer from coming back. About 154 adults with advanced but operable cancer will get either toripalimab alone or with chemo for two cycles, then have surgery…

This study tests whether low-dose atropine eye drops (0.05%) can slow down worsening nearsightedness in children aged 1 to 7 who have had cataract surgery with an artificial lens implant. Fifty children will receive the drops for 12 months, and researchers will measure changes in…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This study tests a combination of three drugs (docetaxel, nimotuzumab, and pucotenlimab) in 30 adults with recurrent or metastatic head and neck cancer that has not responded to previous treatments. The goal is to see if this therapy can shrink tumors and improve survival. Partic…

This study tests whether a one-time booster dose of the Gardasil-9 vaccine can lengthen the time between surgeries for adults with recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths keep coming back in the airway. Researchers will enroll 50 adults…

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus, such as nasopharyngeal cancer, gastric cancer, and lymphoma. The treatment aims to help the immune system recognize and attack cancer cells. Researchers will check safety a…

This study tests whether adding fianlimab to the standard cemiplimab plus chemotherapy can better shrink tumors in adults with advanced HPV-positive head and neck cancer. About 90 participants will receive either the two-drug or three-drug combination before radiation. The goal i…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This phase II trial tests whether surgically cutting the lingual nerve (which controls tongue sensation) can make chemoimmunotherapy work better for people with advanced tongue cancer. 69 adults with stage T3/T4 tongue cancer will receive the nerve cut along with two cycles of ti…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial treatment. First, patients receive a targeted drug (MRG003) plus an immunotherapy (PD-1) for six weeks. Then, they take a chemotherapy pill (capecitabine) with the immunothera…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This study tests whether people with advanced head and neck cancer who respond to immunotherapy can safely have a smaller, less invasive surgery than usual. The goal is to preserve organ function and quality of life without lowering the chance of survival. About 356 participants …

This phase 2 trial tests a combination of two targeted drugs (sintilimab and nimotuzumab) plus chemotherapy for people with advanced head and neck cancer that hasn't spread. The goal is to see if this approach can shrink tumors enough to avoid removing the larynx (voice box). The…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This study compares two surgical techniques for preventing regrowth of a pterygium, a non-cancerous eye growth. After removing the growth, surgeons will cover the area with either a rotated flap of nearby tissue or a free graft from under the eyelid. 342 patients will be randomly…

This study tests whether it is safe to skip radiation to a specific neck area (Level Va) in patients with a type of throat cancer called nasopharyngeal carcinoma. About 474 newly diagnosed patients without cancer spread will be randomly assigned to standard radiation or a reduced…

This study tests whether giving two drugs (pembrolizumab and MRG-003) before standard chemoradiation can shrink tumors in people with advanced nasopharyngeal cancer linked to Epstein-Barr virus. About 35 adults with stage III-IVa disease will receive 3 cycles of the drug combo, t…

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This study tests whether taking a short course of capecitabine pills before surgery can shrink tumors and improve outcomes for people with HPV-negative head and neck cancer. About 75 adults with stage III or IVa cancer will be randomly assigned to either standard care or capecita…

This study tests whether the drug hetrombopag can prevent severe low platelet counts caused by chemotherapy in people with nasopharyngeal carcinoma. About 35 patients who already had low platelets during a previous chemo cycle will take hetrombopag tablets daily during their next…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This study tests whether adding chemotherapy to immunotherapy works better than immunotherapy alone for people with advanced nasopharyngeal cancer whose cancer did not fully respond to initial treatment. About 516 adults aged 18-65 with stage II-III disease will receive either th…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests a lower dose of radiation (12 Gy in 6 sessions) for people with low-grade B-cell orbital lymphoma, a slow-growing eye cancer. The goal is to see if this dose can control the tumor as well as the standard higher dose (24-25 Gy) while causing fewer long-term side e…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This early-stage trial tests whether immune cells taken from a patient's own tumor (TIL) can be safely given directly into the liver or through a vein to fight metastatic melanoma. 18 adults with advanced uveal or cutaneous melanoma that has spread will receive TIL along with che…

This phase III trial tests whether adding the immunotherapy drug serplulimab to standard induction chemotherapy can allow patients with advanced nasopharyngeal cancer to skip concurrent chemotherapy during radiation. The study plans to enroll 456 adults aged 18-65 with stage II-I…

This pilot study will test whether a fish oil-enriched nutritional supplement, combined with weekly nutrition counseling, is feasible and safe for people with head and neck cancer undergoing chemoradiotherapy. Fifteen participants will start taking the supplement two weeks before…

This study tests whether extra dental care every three months for three years can prevent or reduce late side effects like dry mouth, cavities, and jaw stiffness in head and neck cancer survivors. 300 adults who completed radiation or chemoradiation will either get this extra sup…

This early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…

This phase II trial tests whether giving pembrolizumab (an immunotherapy) plus chemotherapy before surgery, followed by maintenance pembrolizumab, can improve outcomes for people with locally recurrent nasopharyngeal carcinoma. About 53 participants will receive up to 6 cycles of…

This early-phase trial is testing a new approach for people with recurrent or metastatic head/neck cancer or esophageal cancer. The treatment combines a virus that delivers endostatin directly into tumors with an immunotherapy drug (PD-1 inhibitor). The goal is to see if the comb…

This study tests a new radioactive tracer called 64Cu-DOTA-ECL1i that aims to make PET scans more accurate for head and neck cancer. Researchers will enroll 90 adults with newly diagnosed or recurrent/metastatic head and neck squamous cell carcinoma. The goal is to see if this tr…

This early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is t…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study aims to see if a simple blood test can find HPV-related oropharyngeal cancer early in men aged 50 and older who have no symptoms. Researchers will check blood for two markers of HPV and then follow up with those who test positive to find and treat any tumors. If succes…

This study will test artificial intelligence algorithms that analyze video from routine endoscopies of the head and neck. The AI will try to detect, classify (benign vs. malignant), and outline lesions, comparing its performance to doctors and lab results. About 283 adults with s…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This early-phase trial tests a fluorescent dye called ABY-029 that may help surgeons see head and neck cancer during surgery. About 24 adults with head and neck squamous cell carcinoma will receive a tiny amount of the dye before surgery. Researchers will check safety and find th…

This study tests whether a special PET scan (18FET) can find small pituitary tumors that standard MRI scans miss. About 30 adults with suspected hormone-secreting pituitary tumors will receive the scan. If it works, it could help doctors decide on surgery or radiation without nee…

This study will collect thousands of photos of mouth lesions from patients seen over 50 years at a French hospital. Experts will review each photo to confirm the diagnosis. Researchers will then use these images and patient data to train an AI system to automatically identify can…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

This study will test whether a special CT scan (dual-energy CT) can be as good as MRI for mapping tumors and healthy organs before radiation therapy. Researchers will enroll 80 people with brain, bone, head/neck, or lung cancer. If DECT works well, it could save time and money co…

This early-phase study will test a new radioactive tracer called [18F]-AraG in just 5 people with advanced head and neck cancer. Participants will receive two PET/CT scans (before and during standard chemoradiotherapy) to see if the tracer's uptake matches immune cell activity an…

This Phase 2 trial tests whether psilocybin, a psychedelic compound, can prevent or lessen chemotherapy-induced peripheral neuropathy (nerve damage) in people with breast, colorectal, or head and neck cancer. About 83 participants will receive either psilocybin, a low-dose placeb…

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This pilot study tests two light therapy devices—one placed inside the mouth and one outside—to prevent and treat painful mouth sores caused by radiation therapy. Sixty adults with oral cavity or oropharynx cancer will receive light sessions twice a week for prevention, then thre…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This pilot study tests whether placing a soft tissue matrix over a nerve during forearm flap surgery can prevent chronic pain and numbness. Eighty head and neck cancer patients will be randomly assigned to receive either the matrix or standard closure. The main goal is to see if …

This study tests whether removing a thin layer of tissue (pseudomembrane) from the back of the nose using a scope can prevent radiation-induced tissue death in patients with recurrent nasopharyngeal cancer who have had repeat radiation. About 40 adults in China will undergo the p…

This study tests whether a modified herbal mouthwash can prevent painful mouth sores caused by radiation therapy in people with head and neck cancer. About 156 participants will use either the herbal mouthwash or a placebo during their radiation treatment. The goal is to see if t…

This study tests if a special light (photobiomodulation) can prevent and treat painful mouth sores caused by chemotherapy in children aged 4-17 with cancer. Half of the 49 participants will get light therapy, and the other half will get a standard gel. The goal is to see if the l…

This study tests an oral spray made from stem cell exosomes to prevent severe mouth sores in head and neck cancer patients undergoing radiation. 200 participants will use the spray three times daily, starting a week before radiation and continuing for two weeks after. The goal is…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

This study tests whether a steroid nasal spray can prevent fluid buildup in the middle ear, a common side effect of radiation therapy for nasopharyngeal cancer. About 168 adults who are about to start radiation will use either the spray or a placebo for 12 months. The goal is to …

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This trial compares early versus delayed acupuncture to reduce dry mouth caused by chemoradiation in head and neck cancer patients. Participants receive acupuncture either during chemoradiation or after, and their dry mouth symptoms are tracked for a year. The goal is to find the…

This study tests whether adding palliative care early — alongside standard chemoradiotherapy — can improve symptoms and quality of life for people with advanced head and neck cancer that cannot be surgically removed. Researchers will compare two groups: one receiving standard tre…

This phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …

This trial tests whether a one-on-one peer support program is feasible for people with head and neck cancer. Patients (mentees) are matched with cancer survivors (mentors) for emotional and informational support. The study will enroll 56 participants and measure how many actually…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This early study tests a new type of radiation therapy called ConformalFLASH, which delivers radiation at an ultra-high speed. It is for 10 adults with head and neck cancer who need a second round of radiation but cannot have surgery. The goal is to see if this fast treatment is …

This phase 2 trial tests a dye called bevonescein that makes nerves glow during thyroid surgery, helping surgeons see and avoid them. Forty adults having thyroid removal will receive the dye before surgery. The main goal is to see if it improves voice outcomes by reducing nerve i…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study tests whether an AI-powered physiotherapy system can help oral cancer patients improve mouth, neck, and shoulder movement after surgery or radiation. Fifteen participants will use the system for 4 to 6 weeks, doing daily exercises prescribed by the AI. The goal is to s…

This study tests a coordinated rehab program for 74 veterans with head and neck cancer. The program combines standard swallowing therapy with proactive hearing and balance checks and a nurse assessment to find other rehab needs. The goal is to reduce stress and improve well-being…

This study tests if a ketamine oral rinse can relieve pain from mouth sores (mucositis) caused by radiation therapy in head and neck cancer patients. About 62 adults receiving radiation will use the rinse and report their pain levels. The goal is to see if this simple rinse impro…

This study compares two ways to lift the soft palate during throat surgery to see which causes fewer injuries. About 138 people aged 2 to 70 who need this type of surgery will be randomly assigned to either the standard double-strap method or a new full-wrap method. The goal is t…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This phase 2 trial tests whether taking taurine (a common amino acid) can prevent or reduce severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. 130 patients will take taurine pills or receive standard care starting 3 days before radiation until 1 …

This study tests whether a common antibiotic ointment applied inside the nose can reduce severe mouth and throat pain caused by radiation therapy in head and neck cancer patients. About 126 participants will receive either the antibiotic or a placebo, and neither they nor their d…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests whether daily soaks with normal saline (salt water) can reduce severe skin reactions caused by radiation therapy. About 150 adults with head and neck cancer or sarcoma will either get standard care or standard care plus a 5-10 minute saline soak each day. Researc…

This study develops and tests a support program for cancer survivors who worry about their cancer returning. 150 adults who finished treatment for breast, head and neck, colon-rectal, or prostate cancer will join. Depending on their level of fear, they will receive education, psy…

This study tests if a daily protein drink can lower the chance of severe mouth sores caused by radiation therapy in people with head and neck cancer. About 504 adults will either get the protein supplement or a placebo drink without protein during their radiation treatment. The g…

This study looks at whether bringing in palliative care early during an unplanned hospital stay can reduce aggressive treatments at the end of life for people with advanced cancer. About 493 adults with metastatic digestive, gynecological, ENT, or sarcoma cancers will be randomly…

This study tests whether a new way of aiming radiation beams (non-coplanar) can reduce side effects like dry mouth and swallowing problems in people with head and neck cancer. About 70 adults with cancer of the mouth or throat will be randomly assigned to standard or new radiatio…

This study is for people with HPV-related oropharyngeal (throat) cancer, which often responds well to treatment. The goal is to see if lowering the radiation dose to certain areas can reduce side effects like dry mouth without hurting the chance of curing the cancer. About 132 pa…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study compares two skin-protective strategies—a fragrance-free emollient plus foam dressing versus a silicone-based barrier film—in 104 head and neck cancer patients receiving TomoTherapy. The goal is to see which approach better prevents or reduces painful radiation dermati…

This study tests whether rinsing with hydrogen water can reduce mouth inflammation and pain in people recovering from oral cancer surgery that used a free flap reconstruction. Thirty-six participants will use hydrogen water or plain water for oral care over 7 days. Researchers wi…

This study tests whether a mobile app with swallowing exercises can help people with oral cancer recover better after reconstructive surgery. About 72 adults in Taiwan will either get standard care or standard care plus the app. Researchers will measure swallowing function, anxie…

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

This study will test whether rinsing with cold water (15-20°C) reduces mouth soreness and improves comfort compared to room-temperature water in 200 head and neck cancer patients undergoing radiotherapy. Participants will rinse four times daily for six weeks. The goal is to see i…

This study compares two ways to rebuild the nose after partial or total loss: surgery using skin flaps, or a custom-made prosthetic nose (epithesis). Researchers will ask people who had either treatment at least one year ago to fill out a questionnaire about how their nose looks …

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study looks at how to safely place a breathing tube in people with acromegaly, a condition that can cause changes in the face and airway. It compares two methods: direct laryngoscopy and video laryngoscopy. The goal is to find which method gives a better view of the airway a…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pem…

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study looks at whether giving patients clear, standardized instructions before and after pituitary surgery can improve their recovery. Researchers will compare hospital stay length, complication rates, and unplanned readmissions in 102 adults having elective surgery. The goa…

This study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…

This study will collect data from 10,000 people undergoing upper endoscopy to build an AI model that predicts the risk of developing stomach or esophageal cancer. Researchers will combine information from endoscopy images, tissue samples, genetics, and gut bacteria. Participants …

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study aims to understand the different cell types in oral cancer and pre-cancerous mouth lesions. Researchers will analyze tissue and blood samples from 150 participants to map gene activity and cell interactions. They will also test whether a simple brush sample can replace…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This early-phase trial tests an artificial intelligence system that watches live video from pituitary tumor surgeries performed through the nose. The AI identifies anatomy, instruments, and surgical steps, displaying its analysis on tablets for the surgical team (not the lead sur…

This study looks at whether a supervised, home-based exercise program before surgery is possible and helpful for people with head and neck cancer. About 66 patients will take part, doing physical activities at home with weekly phone check-ins. The goal is to see if this approach …

This study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…

This study follows 120 people with laryngeal cancer to see how their quality of life, voice, swallowing, pain, and mood change before treatment and at 3, 6, and 12 months after. Researchers will use questionnaires to track these changes. The goal is to better understand recovery …

This study will look back at the medical records of 150 children with retinoblastoma who received additional eye treatments after initial chemotherapy. The treatments include radioactive plaque therapy, freezing therapy, or laser therapy. The goal is to see how often each treatme…

This study will use artificial intelligence to create a risk prediction model for head and neck cancers, including cancers of the throat and voice box. Researchers will collect data from 3000 participants, including their medical history, lifestyle habits, and laryngoscopy images…

This study tests a wireless patch that sticks to the face to monitor facial nerves during surgery, aiming to prevent nerve damage. It will be used alongside standard needle-based monitoring in 20 adults having parotid or facial surgery. Researchers will compare how well the patch…

This study tests whether injecting two dyes around the tumor and into cancerous lymph nodes can help surgeons spot hidden cancer spread in head and neck cancer. Twenty adults with oral cavity or head and neck skin cancer will receive the dyes before surgery. The goal is to see if…

This trial tests a new communication workflow called CORRECT that helps radiologists and radiation oncologists work together more effectively when planning radiation therapy for lung and head-and-neck cancers. About 194 patients will be involved, and doctors will use a shared sys…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study follows 50 adults who have had head and neck cancer and now use custom dental prostheses. Researchers will measure how well they chew food and how their quality of life changes over time. The goal is to understand the real-world benefits of these prostheses for cancer …

This study will collect tumor and blood samples from 120 people with head and neck squamous cell carcinoma. Researchers will create mouse models from the samples and analyze molecular markers to understand resistance to standard therapies. The goal is to find new treatment target…

This study looks at how cancer and its treatments change the way people experience food, including taste, mouth health, and overall eating pleasure. Researchers will ask 180 adults with different cancers to fill out a detailed questionnaire about their eating habits and feelings.…

This study looks at how surgery for a rare brain tumor called craniopharyngioma might change what foods people like, especially fatty and sugary ones. Researchers will compare food preferences of 346 adults who had this surgery with two other groups: people who had a different pi…

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. …

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study will test whether a device called the Hypotension Prediction Index (HPI) can help doctors keep blood pressure stable during oral cancer surgery. About 100 adults having oral cancer surgery with flap reconstruction will take part. Half of the surgeries will use the HPI …

This study looks at patients with a type of throat cancer (nasopharyngeal carcinoma) whose tumors did not shrink after two rounds of chemotherapy. It compares two different next steps: switching to a different chemotherapy combination before radiation, or going straight to radiat…

This study creates a tissue bank and data registry for people with recurrent head and neck cancer. Researchers will collect samples and health information from thousands of participants to better understand the disease and find better treatments. The goal is to improve survival a…

This study will measure tongue strength and biting force in 40 mouth cancer patients who use a special plate called an obturator to help them swallow. Researchers want to see how these measurements relate to what patients eat each day. The goal is to better understand how to impr…

This pilot study will test whether trained community health navigators can help head and neck cancer patients get diagnosed and treated faster after an emergency room visit. The navigators will call or text patients to help with barriers like transportation, insurance, or housing…

This study is a long-term follow-up for 100 people who completed a previous trial of bel-sar, an experimental treatment for early choroidal melanoma (a type of eye cancer). Participants will not receive any new treatment but will be monitored for about 5 more years to check for s…

This study tests a culturally tailored communication tool to help dentists discuss oral and pharyngeal cancers with Black men. Researchers will train dental providers and then pilot the tool in community settings with 50 Black men. The goal is to see if the tool improves comfort,…

This study looks for biological markers in people with nasopharyngeal carcinoma to help predict how the disease will progress and how well treatments might work. Researchers will analyze tissue samples from 60 newly diagnosed patients who have not had their cancer spread. The goa…

This study aims to better predict how head and neck cancer responds to chemoradiotherapy. Researchers will use MRI, PET/CT scans, and blood/tumor DNA tests from 152 patients to build a combined prediction model. The goal is to identify which patients have a complete response with…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This study will look at tissue samples from 600 people with nasopharyngeal carcinoma to understand how the tumor's immune environment changes over time. The goal is to find markers that predict how well immunotherapy will work and to identify new treatment targets. Participants m…

This observational study will test whether two new types of PET/CT scans can more accurately stage nasopharyngeal carcinoma and predict how well patients respond to immunotherapy before treatment. About 732 participants aged 18-70 with newly diagnosed, untreated cancer will recei…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study will use ultrasound to measure changes in a shoulder muscle (upper trapezius) in 10 oral cancer patients who had neck surgery and physical therapy. The goal is to see if ultrasound can track muscle recovery and relate it to how well patients can move their arm. It is a…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…